Please login to the form below

Not currently logged in
Email:
Password:

UCB appoints GSK's Mark Bodmer as head of immunology

Also promotes Michele Antonelli to managing director of UCB France

UCB has appointed Mark Bodmer as head of immunology in its New Medicines research and early development division.

The company has also promoted Michele Antonelli to managing director of UCB France. He previously worked as head of the company's technical operations and quality team, a position that will now be filled by UCB's chief operating officer Mark McDade.

Mark Bodmer - UCB, head of immunologyMichele Antonelli - UCB, MD France
Mark Bodmer and Michele Antonelli

Bodmer joins the Belgium-based pharma company from GlaxoSmithKline (GSK), where he most recently served as senior VP of Immuno-Inflammation, Medicines, Discovery and Development.

In his new role Bodmer will be based at UCB's Slough, UK research site. He will sit on the New Medicines leadership team and report to the division's president Ismail Kola.

In a statement, UCB said: “To date Mark's career has spanned research leadership, corporate leadership and business development and we are looking forward to the wealth of experience he will bring to UCB.”

Bodmer is the third new member of the New Medicines leadership team to have recently joined UCB, following the appointments of Duncan McHale as head of global exploratory development and Peter Theil as head of non-clinical development.

UCB's New Medicines is based around two European research hubs - Braine-l'Alleud in Belgium for central nervous system (CNS) diseases and Slough for immunological disorders – whose work covers discovery research through to clinical proof of concept.

Earlier this year UCB New Medicines signed a $6m collaboration with Harvard University in the US. The first project to be funded was a study looking at developing antibodies with potential in diabetes and metabolic disorders.

5th January 2012

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
AMICULUM Limited

AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >220 healthcare communications professionals,...

Latest intelligence

Virtual Hackathon on Healthcare Innovation: a Customer Story
How participants from 9 different countries in the APAC region were brought together to participate in a pharmaceutical company-wide 3-day virtual "hackathon," with spectacular results....
OPEN Health at the World Orphan Drug Conference USA
Our Director of Rare Disease, Gavin Jones looks forward to his conversation with Emily Crossle & Betsy Bogard at #WODCUSA2020 !...
Can involving patients in design transform the clinical trial experience?
While the research space is a heavily regulated environment and there are rules that we must abide by, this doesn’t mean clinical study materials have to be ‘boring’ or the...

Infographics